NCT03860597

Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: University of California, San Diego · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory processing fidelity (APF) and auditory learning.

Conditions

• Schizophrenia
• Schizo Affective Disorder
• Schizoaffective Disorder
• Healthy

Interventions

Type	Name	Description
DRUG	Memantine	To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
DRUG	Placebos	To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.

Timeline

• Start date: 2018-04-01
• Primary completion: 2021-03-31
• Completion: 2021-03-31
• First posted: 2019-03-04
• Last updated: 2022-12-21
• Results posted: 2022-12-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study